Glycorex Transplantation AB (publ.) announced that the Transfusion unit at the University of Rochester Medical Center presents their experience with the UBP-product for the manufacturing of low titer-blood group O whole blood (LTOWB) at the Society for the Advancement of Blood Management (SABM) on September 24, 2021. The company has developed a CE-marked medical device for reduction of blood group A and blood group B specific antibodies (UBP-product). Massive bleeding is one of the leading causes of death in severe trauma. Evidence is growing suggesting that transfusion of whole blood is most appropriate in this setting, however the availability of blood group O whole blood with low levels (titers) of blood group antibodies (anti-A/B antibodies) is limited. Thus, products or methods for the manufacturing of LTOWB for use in massive transfusion may prove to be of significant clinical value in both civilian and military contexts. The company's UBP-product has been tested at the University of Rochester Medical Center (U.S.) for this very purpose: to reduce anti-A/B antibody titers in blood group O whole blood. The results are encouraging as they show that the UBP-product is effective in reducing anti-A/B antibody titers in whole blood units to near zero, without effecting other blood parameters as tested by the complete blood count or thromboelastography assays.